Anemia management in heart failure: A thick review of thin data

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 757-767

  McBride, Brian F ^a,b   White, C Michael ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Anemia; Erythropoietin; Heart failure; Mortality

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; HEART ASSIST DEVICE; HEART FAILURE; HEMODYNAMIC MONITORING; HUMAN; METABOLIC REGULATION; MORBIDITY; MORTALITY; OXYGEN TRANSPORT; PREDICTION; REACTION OPTIMIZATION; REVIEW; SURVIVAL; SYMPTOMATOLOGY;

EID: 2942565665     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.757.36072     Document Type: Review

References (69)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2001.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult; executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2001;38:2101-13.
3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
5. Colucci WS, Packer M, Bristow MR, et al, for the US Carvedilol Heart Failure Study Group. Congestive heart failure/myocardial disease: carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
6. Packer M, Coats AJS, Fowler MB, et al, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
7. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302.
8. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
9. Schmedthje JF, Evans GW, Byerly W, et al. Treatment of chronic heart failure in a managed care setting: baseline results for the achieving cardiac excellence project. N C Med J 2003;64:4-10.
10. White CM. Prevention of suboptimal β-blocker treatment in patients with myocardial infarction. Ann Pharmacother 1999;33:1063-72.
11. McMullan R, Silke B. A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure. Postgrad Med J 2001;77:765-8.
12. Wikstrand J, Hjalmarson A, Waggstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8.
13. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44
14. Rich MW, Shah AS, Vinson JM, Freedland KE, Kuru T, Sperry JC. Iatrogenic congestive heart failure in older adults: clinical course and prognosis. J Am Geriatr Soc 1996;44:638-43
15. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62.
16. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
17. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population based study. J Am Soc Nephrol 2002;13:1928-36.
18. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med 2003;114:112-19.
19. Ezekowitz JA, McAllister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003;107:223-5.
20. Bersin RM, Kwasman M, Lau D, et al. Importance of oxygen-hemoglobin binding to oxygen transport in congestive heart failure. Br Heart J 1993;70:443-7.
21. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998;279:217-21.
22. Levy PS, Kim SJ, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1993;265:H340-9.
23. Eckstein RW. Development of intraarterial coronary anastomoses by chronic anemia: disappearance following correction of anemia. Circ Res 1955;3:306-10.
24. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy 2003;23:997-1020.
25. Florenzano F, Gabriela-Diaz MT, Regonesi C, Escobar E. Left ventricular function in chronic anemia: evidence of noncatecholamine positive inotropic factor in the serum. Am J Cardiol 1984;54:638-45.
26. Bristow MR, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial α- and β-adrenergic receptors in heart failure: is cardiac derived norepinephrine the regulatory signal? Eur Heart J 1988;9:35-40.
27. Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, McThom SA. Racial differences in cardiac structure and function in essential hypertension. BMJ 1994;308:1011-14.
28. Abdellatif M, Schneider MD. Transcriptional circuits mediating cardiac hypertrophy and heart failure. In: Narula J, Virmani R, Ballester M, et al, eds. Heart failure: pathogenesis and treatment. London: Martin Dunitz, 2002:59-67.
29. Ingwall JS. Myocardial energetics and contractility. In: Narula J, Virmani R, Ballester M, et al, eds. Heart failure: pathogenesis and treatment. London: Martin Dunitz, 2002:45-58.
30. Elgert KD, ed. Immunology: understanding the immune system. New York: Wiley-Liss, 1996.
31. Youker K, Smith CW, Anderson DC, et al. Neutrophil adherence to isolated adult cardiac myocytes. J Clin Invest 1992;89:602-9
32. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
33. Oral H, Dorn GW, Mann DL. Sphingosine mediates the intermediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiomyocyte. J Biol Chem 1997;272:4836-42.
34. McDonough P, Yasui K, Betto R, et al. Control of calcium levels: inhibitory actions of sphingosine on calcium transients and L-type calcium channel conductance. Circ Res 1994;75:981-9.
35. Ungureanu-Longrois D, Ballingrand JL, Simmons WW, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res 1995;77:494-502.
36. Ballingrand JL, Ungureanu-Longrois D, Kelly RA, et al. Abnormal contractile function due to induction of nitric oxide synthase in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993;91:2314-19.
37. Liu Y, Cigola E, Cheng W, et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995;73:771-87.
38. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
39. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult ventricular myocytes by activation of the β adrenergic pathway. Circulation 1998;98:1329-34.
40. Anversa P, Hiler B, Ricci R, Guideri G, Olivetti G. Myocyte cell loss and myocyte hypertrophy in the aging rat heart. J Am Coll Cardiol 1986;8:1441-8.
41. Suenobu N, Shichiri M, Iwashina M, Marumo F, Hirata Y. Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 1999;19:141-6.
42. Baliga RR, Chandrashekhar Y, Narula J. Apoptosis in congestive heart failure. In: Narula J, Virmani R, Ballester M, et al, eds. Heart failure: pathogenesis and treatment. London: Martin Dunitz, 2002;293-306.
43. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923-31.
44. Wald MR, Borda ES, Sternin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 1996;167:461-8.
45. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597-605.
46. Ribatti D, Presta M, Vacco A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
47. Halmesmaki E, Teramo KA, Widness JA, Clemons GK, Ylikorkala O. Maternal alcohol abuse is associated with elevated fetal erythropoietin levels. Obstet Gynecol 1990;6:219-22.
48. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor-α in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
49. Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol 1999;178:133-43.
50. Chong ZZ, Kag JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt 1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9.
51. Sun SY, Yue P, Zhou JY, et al. Overexpression of Bcl2 blocks TNF-related apoptosis inducing ligand (TRAIL) induced apoptosis in human lung cancer cells. Biochem Biophys Res Comm 2001;280:788-97.
52. Kim YM, Bombeck CA, Billar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 1999;84:253-6.
53. Wang XQ, Varzi ND. Erythropoietin decreases nitric oxide synthase expression by human endothelial cells. Hypertension 1999;33:894-9.
54. Drexler H, Kastner S, Strobel A, Studer R, Bordde O, Hasenfub G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing heart. J Am Coll Cardiol 1998;32:955-63.
55. Yoshikoa K, Thompson J, Miller MJS, Fisher JW. Inducible nitric oxide synthase expression and erythropoietin production in human hepatocellular carcinoma cells. Biochem Biophys Res Comm 1997;232:702-6.
56. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-6.
57. Jensen JD, Eiskjaer H, Bagger JP, Pedersen EB. Elevated level of erythropoietin in congestive heart failure: relationship to renal perfusion and plasma renin. J Intern Med 1993;233:125-30.
58. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74:468-73.
59. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
60. Reiser PJ, Portman MA, Xue-Han H, Moravec CS. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol 2001;280:H1814-20.
61. Linde T, Sandhagen B, Haag A, Morlin C, Danielson BG. Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study. J Hum Hypertens 1996;10:199-205.
62. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998;13:1206-10
63. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJS, Anker SD. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 2002;39:1901-8
64. Low-Friedrich I, Grutzmacher P, Bergman M, Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 1989;31:26-30.
65. Low-Friedrich I, Grutzmacher P, Marz W, Bergman M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991;11:54-60.
66. Goldberg N, Lundin P, Delano B, Friedman EA, Stein RA. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992;124:424-7
67. Besarb A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998;339:584-90.
68. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
69. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Abdrone AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe heart failure. Circulation 2003;107:294-9.